[1] 王维林,白鑫,屠红,等. 肝癌血清标志物研究的新进展.肿瘤, 2009, 29: 389-392.
[2] 中华人民共和国卫生部.原发性肝癌诊疗规范(2011年版).临床肝胆病杂志,2011,27.
[3] Johnson PJ, Williams R. Serum alpha-fetoprotein estimations and doubling time in hepatocellular carcinoma: Influence of therapy and possible value in early detection. JNCI J Natl Cancer Inst,1980,64:1329-1332.
[4] 张丹,李远,徐泽强,等.外周血肝癌标志物在肝癌诊断中的价值.中华实用诊断与治疗杂志,2011,25:742-744.
[5] Yan J, Zhao QJ, Li GC. Tumor markers for hepatocellular carcinoma. Mol Clin Oncol. 2013,1: 593-598.
[6] Masuda T, Beppu T, Horino K. Preoperative tumor marker doubling time is a useful predictor of recurrence and prognosis after hepatic resection of hepatocellular carcinoma. J Surg Oncol, 2010, 102:490-496.
[7] Roberts SG, Blute ML, Erik J. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer. Mayo Clin Proc, 2001,76: 576-581. |
